Targeted therapies are only as good as the tests that determine whether they are warranted, says this article in the New York Times. In it, Linda Griffith, the head of MIT's Center for Gynepathology Research, says that she has seen this both as a researcher and as a patient. Her Her2 test on a breast biopsy came back as a mosaic and whether or not she should take Herceptin was unclear.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.